Status:
COMPLETED
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
Lead Sponsor:
Chulalongkorn University
Conditions:
End-stage Renal Disease
Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
High-efficiency post-dilution online hemodiafiltration (OL-HDF) using high-flux dialyzer and requiring high blood flow rate (BF ≥400 mL/min) has been reported to enhance protein-bound toxin and middle...
Detailed Description
Elevated protein-bound toxins including p-cresol (pCS) and indoxyl sulfate (IDS) as well as middle-molecular toxins such as beta2-microglobulin (B2M) which could not be removed by hemodialysis (HD) ar...
Eligibility Criteria
Inclusion
- End-stage renal disease patients treated with thrice-a-week OL-HDF for at least 6 months
- Residual urine \< 100 mL/day
Exclusion
- Active cardiovascular disease
- Active malignancy
- Pregnancy
- Breast-feeding
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03288922
Start Date
October 1 2016
End Date
January 1 2018
Last Update
January 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chulalongkorn Hospital
Bangkok, Thailand, 10330